Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

AstraZeneca 1Q

U.S. sales were $3.6 billion (+7%), aided by Toprol-XL sales, up 59% to $288 million, due to the withdrawal of two generic competitors.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 1Q

1Q Revenues: $7.7 billion (flat)

1Q Earnings: $1.6 billion(-15%)

Comments: U.S. sales were $3.6 billion (+7%), aided by Toprol-XL sales, up 59% to $288 million, due to the withdrawal of two generic competitors. Sales in Europe were down 10% to $2.2 billion. Seroquel sales were $1.1 billion (+11%). Crestor sales were up 35% to $969 million. Synagis sales were up 5% to $545 million. Symbicort sales were $515 million (+24%). Pulmicort sales were down 26% to $292 million and Casodex sales were down 27% to $236 million due to generic competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters